Intensive Postpartum Antihypertensive Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-01

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus attenuating the lifelong trajectory of cardiovascular disease risk.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Preeclampsia Postpartum Antihypertensive Treatment

NCT04298034

Preeclampsia Hypertension in Pregnancy

ACTIVE_NOT_RECRUITING PHASE3

Management of Postpartum Preeclampsia

NCT05775744

Postpartum Preeclampsia

COMPLETED NA

Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia

NCT06220721

Hypertension, Pregnancy-Induced

RECRUITING NA

Response to Anti-hypertensives in Pregnant and Postpartum Patients

NCT03506724

Hypertension in Pregnancy Preeclampsia

COMPLETED PHASE4

Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension

NCT04790279

Hypertension in Pregnancy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The IPAT will randomize 60 postpartum patients with HDP at the Medical College of Wisconsin (MCW) to intensive BP control with Nifedipine extended release (ER) (target BP \<140/90 mmHg) versus usual care (target BP \<150/100 mmHg). Oversampling of Black patients with HDP will be done to ensure they comprise 50% of study participants. Patients enrolled in both arms will undergo education on healthy lifestyle following AHA "Life's Essential 8" (LE8) of tobacco cessation, physical activity, healthy sleep, and healthy diet with detailed overview of DASH throughout the first year postpartum with monthly virtual educational session delivered by a registered dietician and a life coach. Assessment of LE8 CVH score will be done after delivery, 6 weeks postpartum, and 12 months postpartum. Participants will also undergo vascular function assessment: endothelial dysfunction with brachial artery flow mediated dilation (FMD), arterial stiffness with carotid-femoral pulse wave velocity (cfPWV) and anti-angiogenic and inflammatory CVD biomarker with soluble fms-like tyrosine kinase (sFlt-1), at baseline, 6 weeks, and 12 months postpartum. The primary outcome is feasibility of all study procedures, including recruitment, retention, and adherence. Secondary outcomes are change in BP, CVH score, FMD, PWV, and sFlt-1 from baseline to 12 months postpartum.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertensive Disorder of Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention arm

Intervention group - intensive postpartum BP control with Nifedipine initiation at SBP≥140 mmHg or DBP≥90 mmHg and maintaining BP at \<140/90 mmHg during the first 6 weeks postpartum. In addition, participants will receive education on healthy lifestyle following AHA LE8.

Group Type EXPERIMENTAL

Nifedipine ER

Intervention Type DRUG

Postpartum BP treatment to \<140/90 mmHg

Active control arm

Active control group - a group of usual care that follows ACOG recommendations with Nifedipine initiation at SBP≥150 mmHg or DBP≥100 mm Hg and maintaining BP at \<150/100 mmHg during the first 6 weeks postpartum. In addition, participants will receive education on healthy lifestyle following AHA LE8.

Group Type ACTIVE_COMPARATOR

Nifedipine ER

Intervention Type DRUG

Postpartum BP treatment to \<140/90 mmHg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nifedipine ER

Postpartum BP treatment to \<140/90 mmHg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tight BP control group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HDP diagnosis (gestational hypertension or preeclampsia) according to ACOG guidelines
* Postpartum day 0-3 and prior to discharge
* Able to communicate in English or in Spanish
* Age 18 - 45

Exclusion Criteria

* Pre-gestational hypertension
* Pre-gestational diabetes ( type 1 or type 2)
* Intent to transfer postpartum to an outside institution of the participating centers
* Known allergy to nifedipine or other significant contraindication to nifedipine
* Inability or unwillingness to provide informed consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes